The stars are aligning for several biotech stocks. Thirty-five billion stars in fact. That huge number in dollars represents the potential annual spending needed to treat one of the biggest and growing problems facing the healthcare sector today. We’re talking about NASH.
Most often occurring in obese or glucose-intolerant people, Nonalcoholic Steatohepatitis or NASH is quickly increasing in prevalence. The progressive liver disease can destroy the organ and is projected to become the leading cause of all liver transplants by 2020. For those nations with fatty diets, the prevalence of NASH are estimated to be as much as 20% of the total population. Here in the U.S., roughly 15 million are estimated to be in the various stages of the disease. This is a massive and quickly growing problem. And right now, there are no approved treatments for NASH.
But several biotech stocks are trying to crack the NASH code. If just one is successful, it could result in blockbuster-sized revenues. It’s as tantalizing of a trend as there is in healthcare.
For investors looking at biotech stocks, NASH is simply where it’s at. Which pharma stocks are taking a serious look at NASH? Here are five biotech stocks tackling the problem head-on.
Intercept Pharmaceuticals (ICPT)；
Gilead Sciences (GILD)；
Madrigal Pharmaceuticals Inc (MDGL)；
Viking Therapeutics (VKTX)；
Galectin Therapeutics (GALT)；